| 5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil |
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. |
zacks.com |
2025-05-15 13:11:13 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript |
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Nelson Cox - Lake Street Ross Osborn - Cantor Fitzgerald Priya Sachdev - UBS Rohin Patel - JPMorgan Michael Polark - Wolfe Research Operator Greetings and welcome to the NeuroPace First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-14 02:33:37 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates |
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-05-13 22:25:33 |
Czytaj oryginał (ang.) |
| NeuroPace Reports First Quarter 2025 Financial Results |
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif. |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, NeuroPace (NPCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-05-13 13:50:56 |
Czytaj oryginał (ang.) |
| NeuroPace Provides Update on Tariff Status |
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- |
globenewswire.com |
2025-04-14 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting |
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82% at 3 years. Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif. |
globenewswire.com |
2025-04-08 12:00:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting |
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. |
globenewswire.com |
2025-04-03 12:00:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Refocusing of Product Portfolio |
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfolio on its core, differentiated RNS System product line, it is terminating its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference |
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025. |
globenewswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript |
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-04 21:45:37 |
Czytaj oryginał (ang.) |
| NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results |
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- |
globenewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference |
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. |
globenewswire.com |
2025-03-03 23:15:00 |
Czytaj oryginał (ang.) |
| NeuroPace to Present at the Leerink Partners Global Healthcare Conference |
MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, January 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. |
globenewswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains? |
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-02-21 08:15:20 |
Czytaj oryginał (ang.) |
| NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. |
MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company's common stock from KCK Ltd. The repurchase of these shares allowed for the organized sale by KCK Ltd. of all remaining shares it held in the Company. NeuroPace funded the repurchase of these shares using a portion of the proceeds from its recent underwritten public offering. NeuroPace also strengthened its balance sheet following the closing of the public offering, which the Company now anticipates will be sufficient to support its planned operations until achieving cash flow breakeven. Additionally, the Company terminated its current at-the-market (ATM) offering program. |
globenewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 |
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares |
MOUNTAIN VIEW, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $10.00 per share, including 975,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. |
globenewswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock |
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. |
globenewswire.com |
2025-02-14 08:33:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock |
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares are being offered by NeuroPace. In addition, NeuroPace intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-02-13 18:34:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th |
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego. |
globenewswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Issues 2025 Financial Guidance Targets |
– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually here, and the accompanying slide presentation can be accessed here). |
globenewswire.com |
2025-01-28 19:15:00 |
Czytaj oryginał (ang.) |
| NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock? |
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-22 08:36:11 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates |
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? |
NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-12-25 15:01:14 |
Czytaj oryginał (ang.) |
| NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. |
globenewswire.com |
2024-12-18 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace to Host Investor Day on January 28th in New York City |
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City. |
globenewswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-06 12:55:28 |
Czytaj oryginał (ang.) |
| NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting |
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatment experience for physicians and patients NeuroPace's Booth #2119 MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 2024 American Epilepsy Society Annual Meeting (AES 2024). |
globenewswire.com |
2024-12-04 18:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome |
Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy |
globenewswire.com |
2024-12-03 18:05:00 |
Czytaj oryginał (ang.) |
| What Makes NeuroPace (NPCE) a New Buy Stock |
NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-18 15:00:39 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade |
The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-18 13:00:42 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript |
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-12 21:59:47 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates |
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago. |
zacks.com |
2024-11-12 21:06:30 |
Czytaj oryginał (ang.) |
| NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy |
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? |
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-28 11:05:48 |
Czytaj oryginał (ang.) |
| NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024 |
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-10-22 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Continues to Strengthen Management Team |
Appoints experienced people leader as Vice President of Human Resources Appoints experienced people leader as Vice President of Human Resources |
globenewswire.com |
2024-10-16 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Strengthens Management Team with Two Key Appointments |
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. |
globenewswire.com |
2024-09-04 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences |
MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September. |
globenewswire.com |
2024-08-27 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace to Participate in Upcoming Healthcare Conferences in September |
MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA. |
globenewswire.com |
2024-08-22 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroPace: Only For Those With Strong Nerves |
NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. NeuroPace stock is displaying substantial volatility and looks interesting on a highly speculative basis, anticipating wider approval of RNS. |
seekingalpha.com |
2024-08-20 17:01:04 |
Czytaj oryginał (ang.) |
| NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up |
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter. |
zacks.com |
2024-08-20 12:40:54 |
Czytaj oryginał (ang.) |
| NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript |
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Robert Marcus - JP Morgan Michael Polark - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2024-08-14 02:22:10 |
Czytaj oryginał (ang.) |